Evaluating the Use of Environmental and Polygenic Risk Scores to Inform Colorectal Cancer Risk-Based Surveillance Intervals

Overview

Journal Clin Transl Gastroenterol

Specialty Gastroenterology

Date 2024 Dec 29

PMID 39733276

Authors

Rebecca Landy

Hormuzd A Katki

Wen-Yi Huang

Difei Wang

Minta Thomas

Flora Qu

Neal D Freedman

Erikka Loftfield

Jianxin Shi

Ulrike Peters

Li Hsu

Robert E Schoen

Sonja I Berndt

Affiliations

Soon will be listed here.

Abstract

Introduction: United States Multi-Society Task Force colonoscopy surveillance intervals are based solely on adenoma characteristics, without accounting for other risk factors. We investigated whether a risk model including demographic, environmental, and genetic risk factors could individualize surveillance intervals under an "equal management of equal risks" framework.

Methods: Using 14,069 individuals from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial who had a diagnostic colonoscopy following an abnormal flexible sigmoidoscopy, we modeled the risk of colorectal cancer, considering the diagnostic colonoscopy finding, baseline risk factors (e.g., age and sex), 19 lifestyle and environmental risk factors, and a polygenic risk score for colorectal cancer. Ten-year absolute cancer risks for each diagnostic colonoscopy finding (advanced adenomas [N = 2,446], ≥3 non-advanced adenomas [N = 483], 1-2 non-advanced adenomas [N = 4,400], and no adenoma [N = 7,183]) were used as implicit risk thresholds for recommended surveillance intervals.

Results: The area under the curve for the model including colonoscopy findings, baseline characteristics, and polygenic risk score was 0.658. Applying the equal management of equal risks framework, 28.2% of individuals with no adenoma and 42.7% of those with 1-2 non-advanced adenomas would be considered high risk and assigned a significantly shorter surveillance interval than currently recommended. Among individuals who developed cancer within 10 years, 52.4% with no adenoma and 48.3% with 1-2 non-advanced adenomas would have been considered high risk and assigned a shorter surveillance interval.

Discussion: Using a personalized risk-based model has the potential to identify individuals with no adenoma or 1-2 non-advanced adenomas, who are higher risk and may benefit from shorter surveillance intervals.

References

Castle P, Katki H . Screening: A risk-based framework to decide who benefits from screening. Nat Rev Clin Oncol. 2016; 13(9):531-2. PMC: 5505517. DOI: 10.1038/nrclinonc.2016.101. View

Cross A, Robbins E, Pack K, Stenson I, Kirby P, Patel B . Long-term colorectal cancer incidence after adenoma removal and the effects of surveillance on incidence: a multicentre, retrospective, cohort study. Gut. 2020; 69(9):1645-1658. PMC: 7456728. DOI: 10.1136/gutjnl-2019-320036. View

Kahi C, Imperiale T, Juliar B, Rex D . Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol Hepatol. 2009; 7(7):770-5. DOI: 10.1016/j.cgh.2008.12.030. View

He X, Hang D, Wu K, Nayor J, Drew D, Giovannucci E . Long-term Risk of Colorectal Cancer After Removal of Conventional Adenomas and Serrated Polyps. Gastroenterology. 2019; 158(4):852-861.e4. PMC: 6954345. DOI: 10.1053/j.gastro.2019.06.039. View

Schoen R, Razzak A, Yu K, Berndt S, Firl K, Riley T . Incidence and mortality of colorectal cancer in individuals with a family history of colorectal cancer. Gastroenterology. 2015; 149(6):1438-1445.e1. PMC: 4628587. DOI: 10.1053/j.gastro.2015.07.055. View

Chen H, Liu L, Lu M, Zhang Y, Lu B, Zhu Y . Implications of Lifestyle Factors and Polygenic Risk Score for Absolute Risk Prediction of Colorectal Neoplasm and Risk-Adapted Screening. Front Mol Biosci. 2021; 8:685410. PMC: 8324207. DOI: 10.3389/fmolb.2021.685410. View

Machiela M, Huang W, Wong W, Berndt S, Sampson J, De Almeida J . GWAS Explorer: an open-source tool to explore, visualize, and access GWAS summary statistics in the PLCO Atlas. Sci Data. 2023; 10(1):25. PMC: 9837135. DOI: 10.1038/s41597-022-01921-2. View

McGeoch L, Saunders C, Griffin S, Emery J, Walter F, Thompson D . Risk Prediction Models for Colorectal Cancer Incorporating Common Genetic Variants: A Systematic Review. Cancer Epidemiol Biomarkers Prev. 2019; 28(10):1580-1593. PMC: 7610631. DOI: 10.1158/1055-9965.EPI-19-0059. View

Shaukat A, Kahi C, Burke C, Rabeneck L, Sauer B, Rex D . ACG Clinical Guidelines: Colorectal Cancer Screening 2021. Am J Gastroenterol. 2021; 116(3):458-479. DOI: 10.14309/ajg.0000000000001122. View

10.

Pinsky P, Miller E, Prorok P, Grubb R, Crawford E, Andriole G . Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2018; 123(5):854-860. PMC: 6450783. DOI: 10.1111/bju.14580. View

11.

Prorok P, Andriole G, Bresalier R, Buys S, Chia D, Crawford E . Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2001; 21(6 Suppl):273S-309S. DOI: 10.1016/s0197-2456(00)00098-2. View

12.

Guo F, Edelmann D, Cardoso R, Chen X, Carr P, Chang-Claude J . Polygenic Risk Score for Defining Personalized Surveillance Intervals After Adenoma Detection and Removal at Colonoscopy. Clin Gastroenterol Hepatol. 2022; 21(1):210-219.e11. DOI: 10.1016/j.cgh.2022.03.013. View

13.

Egemen D, Cheung L, Chen X, Demarco M, Perkins R, Kinney W . Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis. 2020; 24(2):132-143. PMC: 7147417. DOI: 10.1097/LGT.0000000000000529. View

14.

Jover R, Bretthauer M, Dekker E, Holme O, Kaminski M, Loberg M . Rationale and design of the European Polyp Surveillance (EPoS) trials. Endoscopy. 2016; 48(6):571-8. PMC: 5412707. DOI: 10.1055/s-0042-104116. View

15.

Lennon N, Kottyan L, Kachulis C, Abul-Husn N, Arias J, Belbin G . Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations. Nat Med. 2024; 30(2):480-487. PMC: 10878968. DOI: 10.1038/s41591-024-02796-z. View

16.

Fernandez-Rozadilla C, Timofeeva M, Chen Z, Law P, Thomas M, Schmit S . Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. Nat Genet. 2022; 55(1):89-99. PMC: 10094749. DOI: 10.1038/s41588-022-01222-9. View

17.

Lee J, Jensen C, Levin T, Doubeni C, Zauber A, Chubak J . Long-term Risk of Colorectal Cancer and Related Death After Adenoma Removal in a Large, Community-based Population. Gastroenterology. 2019; 158(4):884-894.e5. PMC: 7083250. DOI: 10.1053/j.gastro.2019.09.039. View

18.

Wolf A, Fontham E, Church T, Flowers C, Guerra C, LaMonte S . Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018; 68(4):250-281. DOI: 10.3322/caac.21457. View

19.

Cheung L, Egemen D, Chen X, Katki H, Demarco M, Wiser A . 2019 ASCCP Risk-Based Management Consensus Guidelines: Methods for Risk Estimation, Recommended Management, and Validation. J Low Genit Tract Dis. 2020; 24(2):90-101. PMC: 7147416. DOI: 10.1097/LGT.0000000000000528. View

20.

Weissfeld J, Schoen R, Pinsky P, Bresalier R, Church T, Yurgalevitch S . Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst. 2005; 97(13):989-97. DOI: 10.1093/jnci/dji175. View